News & Updates

BPGbio, Inc. acquired substantially all of the assets of Berg, LLC, and licenses from Berg, LLC the use of the Berg and Berg Health names.
-
June 6, 2023 |
Media, News and Updates, Press Releases
BPGbio Announces First Patients Dosed in Phase 2 Trial of AI-Developed BPM 31510 for Glioblastoma Multiforme
read moreBPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that patients have been initially dosed in its Phase 2 trial for BPM 31510 for Glioblastoma Multiforme (GBM), a fast-growing and aggressive form of brain cancer.
-
May 22, 2023 |
Press Releases, Media, News and Updates
BPGbio Announces New Partnership with DoD Focused on AI-Guided Breast Cancer Diagnostics
read moreBPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that it will continue clinical validation of a novel breast cancer diagnostic panel that was developed under a previous agreement with the Department of Defense’s Clinical Breast Care Project (CBCP), including the DoD’s Uniformed Services University of the Health Sciences (USU), The Windber Research Institute, and The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). The new panel, developed with AI, is designed to identify women who are diagnosed with ER+ breast cancer but do not respond to hormone therapy, so that more effective options could be offered to improve treatment response.
-
April 13, 2023 |
Press Releases, News and Updates
BPGbio Announces Oncology Drug Pipeline and Prostate Cancer Biomarker Developments at AACR
read moreBPGbio, Inc., a leading AI-powered biopharma that focuses on oncology, neurology and rare diseases, today announced that novel data insights from its oncology therapeutics and diagnostics portfolio will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, April 14 – 19, 2023.
-
April 12, 2023 |
News and Updates, News Archive
Framingham biotech strikes DOD partnership as it marches toward IPO
read moreTwo months post-acquisition, BPGbio has signed a new, five-year partnership with the Department of Defense and laid out a near-term plan to get to the public markets.
-
March 27, 2023 |
Press Releases, News and Updates, Uncategorized
BPGbio Announces Expanded Partnership with debra of America for BPM 31510 for Epidermolysis Bullosa Phase II/III Trial
read moreBPGbio Inc (BPG), an AI-powered biopharma with a mission to reimagine biology for humanity, announced today that the company has reached a partnership agreement with Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) for BPGbio’s BPM 31510 for Epidermolysis Bullosa Phase II/III trial, which is anticipated to launch in the second half of the year. Through the partnership, debra of America will provide support to awareness, understanding, and key information towards patient recruitment and advocacy for the clinical trial.
-
March 6, 2023 |
News and Updates, Press Releases
BPGbio Announces Appointments to its Leadership Team to Accelerate Research and Commercialization
read more